Form 4: Castle Biosciences CEO Acquires Shares via PSU Vesting
Statement of Changes in Beneficial Ownership
Castle Biosciences CEO Derek J. Maetzold acquired 62,219 shares of common stock through the vesting of performance-based units and received an additional 62,219 performance-based stock units.
Summary
- Derek J. Maetzold, President & Chief Executive Officer and Director of CASTLE BIOSCIENCES INC (CSTL), reported changes in beneficial ownership.
- On January 12, 2026, Maetzold acquired 62,219 shares of Common Stock at a price of $0.
- This acquisition represents 50% of the Performance-Based Stock Units (PSUs) granted on March 4, 2024, which vested due to the satisfaction of certain performance criteria certified by the board of directors.
- Additionally, Maetzold acquired 62,219 Performance-Based Stock Units (PSUs) at a price of $0, representing the remaining 50% of the 2024 PSUs.
- These remaining PSUs will vest subject to the achievement of certain milestones.
- Maetzold's beneficial ownership includes shares held directly and indirectly through various trusts, including The Maetzold Descendants 2020 Trust (52,923 shares), Derek Maetzold 2020 Irrevocable Trust (44,986 shares), several Maetzold 2018 Remainder Trusts (totaling 14,463 shares), and DJM Grantor Retained Annuity Trusts No. 5, 6, and 7 (totaling 148,900 shares).
Sentiment
Score: 7
Explanation: The filing indicates successful achievement of performance targets for executive compensation, which is a positive signal regarding the company's operational performance during the period. It's a routine compensation event, not a major strategic announcement.
Positives
- The vesting of 62,219 Performance-Based Stock Units indicates that certain performance criteria set by the board of directors were satisfied, reflecting positively on company performance during the relevant period.
Future Outlook
The remaining 50% of the 2024 Performance-Based Stock Units (62,219 units) will vest subject to the achievement of specific, undisclosed milestones.
Industry Context
This filing reflects a routine executive compensation event, specifically the vesting of performance-based equity awards, which is a common practice across various industries to align executive incentives with company performance.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Executive Compensation Structure | The board of directors certified the satisfaction of performance criteria for the vesting of 50% of the 2024 Performance-Based Stock Units, demonstrating the application of the company's executive compensation policy. | 01/12/2026 | Reinforces the company's commitment to performance-based compensation, aligning executive incentives with shareholder value creation. |
Related Party Transactions
- Indirect beneficial ownership is reported through various trusts where the reporting person or his family members serve as trustees and/or beneficiaries, including The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, Maetzold 2018 Remainder Trusts, and DJM Grantor Retained Annuity Trusts.
Stakeholder Impact
- Shareholders: The vesting of performance-based units suggests that the company met certain performance targets, which could be viewed positively by shareholders.
- Executive Management: The reporting person, Derek J. Maetzold, directly benefits from the vesting of these equity awards as part of his compensation package.
Next Steps
- The remaining 62,219 Performance-Based Stock Units are expected to vest upon the achievement of certain future milestones.
Key Dates
| Date | Description |
|---|---|
| 03/04/2024 | Grant date of the 2024 Performance-Based Stock Units (PSUs). |
| 01/12/2026 | Date of earliest transaction, representing the vesting of 50% of 2024 PSUs and acquisition of remaining 50% of 2024 PSUs. |
| 01/14/2026 | Signature date of the reporting person's attorney-in-fact. |
Keywords
Castle Biosciences, CSTL, Form 4, Insider Transaction, Performance-Based Stock Units, Executive Compensation, Equity Award, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.